Literature DB >> 33194084

Effect of ERCC2 rs13181 and rs1799793 polymorphisms and environmental factors on the prognosis of patients with lung cancer.

Haorui Zhang1, Yutao Li2, Shicheng Guo3,4, Yi Wang2, Haijian Wang2, Daru Lu2, Jiucun Wang2,5, Li Jin2,5, Gengxi Jiang6, Junjie Wu7, Yiping Han7, Juhong Li8.   

Abstract

PURPOSE: The 5-year survival rate of patients with lung cancer in China is < 20%, and predicting their prognosis is difficult. Here, we investigated the association between two common non-synonymous single-nucleotide polymorphisms (SNPs) in the excision repair cross-complementing 2 (ERCC2) genes (rs13181 and rs1799793) and the prognosis of patients with lung cancer.
METHODS: Genomic DNA was extracted from the blood samples of 839 patients with lung cancer and genotyped using the SNPscan technique. The association between patient prognosis and the ERCC2 genotype was analyzed using a multivariate Cox proportional hazards model adjusted for multiple potential confounders.
RESULTS: The presence of ERCC2 rs13181 T>G significantly increased the risk of death (adjust hazard ratio (HR) = 1.29, 95% CI: 1.06-1.56, P = 0.009). Patients with the rs13181 TG genotype (adjust HR = 1.34, 95% CI: 1.08-1.65, P = 0.007) and rs13181 dominant mode TG+GG (adjust HR = 1.33, 95% CI: 1.08-1.63, P = 0.007) had significantly worse overall survival. Moreover, stratified analyses showed that patients with the TG and TG+GG rs13181 genotypes who were male, elderly (≥60 years), had a history of smoking, or without family history of malignant tumors had a significantly increased risk of death. In patients with adenocarcinoma lung cancer (ADC), the rs1799793 genotype CT (adjust HR = 1.49, 95% CI: 1.06-2.09, P = 0.023) and dominant model CT+TT (adjust HR = 1.45, 95% CI = 1.04-2.02, P = 0.027) were associated with an increased risk of death.
CONCLUSION: ERCC2 rs13181 and rs1799793 SNPs may be significant prognostic factors for the risk of death among patients with lung cancer. AJTR
Copyright © 2020.

Entities:  

Keywords:  ERCC2; lung cancer; prognosis; rs13181; rs1799793; single-nucleotide polymorphism

Year:  2020        PMID: 33194084      PMCID: PMC7653631     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  53 in total

1.  XPD polymorphisms: effects on DNA repair proficiency.

Authors:  R M Lunn; K J Helzlsouer; R Parshad; D M Umbach; E L Harris; K K Sanford; D A Bell
Journal:  Carcinogenesis       Date:  2000-04       Impact factor: 4.944

Review 2.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

3.  Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk.

Authors:  Kim De Ruyck; Marcin Szaumkessel; Isabelle De Rudder; Annelore Dehoorne; Anne Vral; Kathleen Claes; Anja Velghe; Jan Van Meerbeeck; Hubert Thierens
Journal:  Mutat Res       Date:  2007-04-21       Impact factor: 2.433

4.  Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

Authors:  Seok-Hyun Kim; Gyeong-Won Lee; Min Jeong Lee; Yu Ji Cho; Yi Yeong Jeong; Ho-Cheol Kim; Jong Duk Lee; Young Sil Hwang; In-Suk Kim; Suee Lee; Sung Yong Oh
Journal:  Lung Cancer       Date:  2012-05-18       Impact factor: 5.705

5.  Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk.

Authors:  Biyun Qian; Huan Zhang; Lina Zhang; Xiaoying Zhou; Herbert Yu; Kexin Chen
Journal:  Lung Cancer       Date:  2010-12-30       Impact factor: 5.705

Review 6.  DNA and protein adducts in human tissues resulting from exposure to tobacco smoke.

Authors:  David H Phillips; Stan Venitt
Journal:  Int J Cancer       Date:  2012-10-05       Impact factor: 7.396

7.  ERCC1 and ERCC2 variants predict survival in gastric cancer patients.

Authors:  Yangkai Li; Zhensheng Liu; Hongliang Liu; Li-E Wang; Dongfeng Tan; Jaffer A Ajani; Qing-Yi Wei
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

8.  Adverse prognostic impact of TGFB1 T869C polymorphism in non-small-cell lung cancer.

Authors:  Yulan Sang; Xin Bi; Yan Liu; Wei Zhang; Dongjie Wang
Journal:  Onco Targets Ther       Date:  2017-03-10       Impact factor: 4.147

9.  Polymorphisms in XPD gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients: a meta-analysis of 24 studies.

Authors:  Qin Qin; Chi Zhang; Xi Yang; Hongcheng Zhu; Baixia Yang; Jing Cai; Hongyan Cheng; Jianxin Ma; Jing Lu; Liangliang Zhan; Jia Liu; Zheming Liu; Liping Xu; Xinchen Sun
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

Review 10.  Predictive Value of Ercc1 and Xpd Polymorphisms for Clinical Outcomes of Patients Receiving Neoadjuvant Therapy: A Prisma-Compliant Meta-Analysis.

Authors:  Mao Qixing; Dong Gaochao; Xia Wenjie; Yin Rong; Jiang Feng; Xu Lin; Qiu Mantang; Chen Qiang
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

View more
  3 in total

1.  The Relationship between Long Noncoding RNA H19 Polymorphism and the Epidermal Growth Factor Receptor Phenotypes on the Clinicopathological Characteristics of Lung Adenocarcinoma.

Authors:  Yao-Chen Wang; Shih-Ming Tsao; Yia-Ting Li; Chia-Yi Lee; Thomas Chang-Yao Tsao; Ming-Ju Hsieh; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2021-03-11       Impact factor: 3.390

2.  Associations Between CAMKK1 Polymorphism rs7214723 and the Prognosis of Patients With Lung Cancer.

Authors:  Haorui Zhang; Bocen Chen; Zixiu Zou; Jian Feng; Yutao Li; Yi Wang; Xing He; Chang Xu; Haijian Wang; Shicheng Guo; Li Jin; Qiang Li; Jiucun Wang; Man Xiao; Feng Li; Junjie Wu
Journal:  Front Oncol       Date:  2021-11-19       Impact factor: 6.244

3.  The Association of ERCC1 and ERCC5 Polymorphisms with Lung Cancer Risk in Han Chinese.

Authors:  Xueling Lan; Ying Li; Yefeng Wu; Xia Li; Lan Xu
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.